Corvus Pharmaceuticals, Inc.
CRVSNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $909.82M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $6.39$26.95
- Volume (live)
- -
- Avg. volume (3M)
- 1.23M
Corvus Pharmaceuticals (CRVS) Stock Price & Financial Analysis
Corvus Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $9.43 - $10.12 |
|---|---|
| 52-Week High | $26.95 |
| 52-Week Low | $6.39 |
| Open | $9.81 |
| Volume (last close) | 1.04M |
| Average Volume (3M) | 1.23M |
| 50-Day MA | $12.99 |
|---|---|
| 200-Day MA | $14.25 |
| 1-Year Change | +39.91% |
| Market Cap | 909.82M |
|---|---|
| Shares Outstanding | 92.37M |
| Price to Book (P/B) | 4.04 |
| EV/EBITDA | -16.55 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Corvus Pharmaceuticals at a Glance
As of the Oct 16, 2026 close, Corvus Pharmaceuticals (CRVS) has a market capitalization of $909.82M.
As of its latest reported balance sheet, it holds $18.91M in cash and securities against $728.00K of debt, a net cash position of $18.18M.
Corvus Pharmaceuticals does not currently pay a dividend.
The share price is up 39.9% over the past year. At $9.53 (the Oct 16, 2026 close) it sits within its 52-week range of $6.39 to $26.95, below its 200-day moving average of $14.25.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $29.50, 209.5% above the Oct 16, 2026 close.
Frequently Asked Questions About Corvus Pharmaceuticals
What is the current stock price for CRVS?
As of the Oct 16, 2026 close, CRVS stock trades at $9.53. The 52-week range is $6.39–$26.95, with a day range of $9.43–$10.12.
What is the P/E ratio for CRVS?
The P/E ratio (Price-to-Earnings) for CRVS is shown in the Key Statistics section. This valuation metric helps compare Corvus Pharmaceuticals, Inc. to industry peers.
Does CRVS pay dividends?
Corvus Pharmaceuticals does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CRVS?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for CRVS is Buy. The average 12-month price target is $29.50, a 209.5% upside from the Oct 16, 2026 close of $9.53.
What is the market cap of CRVS?
As of the Oct 16, 2026 close, Corvus Pharmaceuticals's market capitalization is $880.3M, classifying it as a small-cap company. Corvus Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.